SILO silopharma.com Total Asset Value of Company

Silo Pharma, Inc. (SILO) is shaping an innovative neuropsychiatric environment by implementing advanced drug delivery methods to combat PTSD and Alzheimer's disease. A steady stream of clinical trial participants is driven by the inefficiency of traditional methods, although the business is constrained by strict FDA and DEA oversight. This chart of total asset price changes, valued at 6.30, confirms the resource allocation strategy across various stages of psychedelic drug development.

The financial stability assessment of Silo Pharma, Inc. (SILO) is based on a set of controlled resources calculated inversely through return on assets (ROA) to eliminate market volatility. This chart of total assets allows for the tracking of the company's actual material base, which is critically important for a biopharmaceutical startup investing capital into costly psychedelic developments for the treatment of depression and Alzheimer's disease.